Clinical Trials Browser

avelumab × 90 days × Clear all

NCT06225596 2026-05-27

Study BT8009-230 in Participants With Locally Advanced or Metastatic Urothelial Cancer (Duravelo-2)

Phase 2 Active not recruiting

Urinary Bladder Neoplasms

NCT03076554 2026-05-22

A Pilot Study to Investigate the Safety and Clinical Activity of Avelumab (MSB0010718C) in Thymoma and Thymic Carcinoma After Progression on Platinum-Based Chemotherapy

Phase 2 Active not recruiting

Parkinson Disease 4, Autosomal Dominant Lewy Body, Thymoma

NCT03324282 2026-05-22

GCISAVE

Phase 2 Terminated

Urinary Bladder Neoplasms

NCT03494322 2026-05-20

EACH

Phase 2 Completed

Carcinoma, Squamous Cell, Head and Neck Neoplasms

NCT05267626 2026-05-18

Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer

Phase 1/2 Recruiting

DermatologicGastrointestinalGenitourinaryHead & NeckThoracic

Diabetes Mellitus, Insulin-Dependent, 10, Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Melanoma, Neoplasm Metastasis, Stomach Neoplasms, Carcinoma, Merkel Cell

NCT06204614 2026-05-18

Drug Screening Using IMD in Bladder Cancer

Phase EARLY_PHASE1 Enrolling by invitation

Muscle Invasive Bladder Urothelial Carcinoma

NCT04068194 2026-05-13

Testing the Combination of New Anti-cancer Drug Peposertib With Avelumab and Radiation Therapy for Advanced/Metastatic Solid Tumors and Hepatobiliary Malignancies

Phase 1/2 Active not recruiting

Gastrointestinal

Gallbladder Neoplasms, Neoplasm Metastasis, Cholangiocarcinoma

NCT04071236 2026-05-13

Radiation Medication (Radium-223 Dichloride) Versus Radium-223 Dichloride Plus Radiation Enhancing Medication (M3814) Versus Radium-223 Dichloride Plus M3814 Plus Avelumab (a Type of Immunotherapy) for Advanced Prostate Cancer Not Responsive to Hormonal Therapy

Phase 1/2 Recruiting

Lymphatic Metastasis, Prostatic Neoplasms

NCT05092958 2026-05-13

Testing the Addition of the Anti-cancer Drug, Cabozantinib, to the Usual Immunotherapy Treatment, Avelumab, in Patients With Metastatic Urothelial Cancer, MAIN-CAV Study

Phase 3 Active not recruiting

Urinary Bladder Neoplasms, Ureteral Neoplasms, Urethral Neoplasms

NCT05947500 2026-05-13

Testing the Combination of Two Anticancer Drugs M1774 (Tuvusertib) and Avelumab to Evaluate Their Safety and Effectiveness in Treating Merkel Cell Skin Cancer, MATRiX Trial

Phase 2 Active not recruiting

Carcinoma, Merkel Cell

NCT03271372 2026-05-12

ADAM

Phase 3 Active not recruiting

Carcinoma, Merkel Cell

NCT06892860 2026-05-06

DISCUS

Phase 2 Recruiting

Urinary Bladder Neoplasms

NCT03217747 2026-05-05

Avelumab, Utomilumab, Anti-OX40 Antibody PF-04518600, and Radiation Therapy in Treating Patients With Advanced Malignancies

Phase 1/2 Active not recruiting

173 enrolled 28 charts

Neoplasm Metastasis, Prostatic Neoplasms

NCT05327686 2026-05-04

SAMURAI

Phase 2 Recruiting

Carcinoma, Renal Cell

NCT05081180 2026-05-01

Study of Avelumab in Combination With Lenvatinib for Children With Primary CNS Tumors

Phase 1 Active not recruiting

Neoplasms, Central Nervous System Neoplasms

NCT04902040 2026-04-30

Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted Antibodies

Phase 1/2 Terminated

19 enrolled 11 charts

GenitourinaryThoracic

Urinary Bladder Neoplasms, Carcinoma, Renal Cell, Lung Neoplasms

NCT05327530 2026-04-24

A Study of the Safety and Efficacy of Various Combinations of Avelumab as Therapy in Locally Advanced or Metastatic Urothelial Carcinoma (JAVELIN Bladder Medley)

Phase 2 Active not recruiting

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT03971409 2026-04-17

InCITe

Phase 2 Active not recruiting

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT07110038 2026-04-16

DEPECA-1 - A Phase II Study to Evaluate a First-line Systemic Therapy With Enfortumab Vedotin Plus Avelumab for Advanced and Metastatic Penile Carcinoma

Phase 2 Recruiting

Penile Squamous Cell Carcinoma (PSCC)

NCT05059522 2026-04-14

Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing

Phase 3 Active not recruiting

Ovarian Neoplasms

NCT03964532 2026-04-09

TALAVE: Induction Talazoparib Followed by Combination of Talazoparib and Avelumab in Advanced Breast Cancer

Phase 1/2 Active not recruiting

Breast Neoplasms

NCT04291885 2026-04-09

I-MAT

Phase 2 Active not recruiting

DermatologicEndocrineNET

Carcinoma, Merkel Cell, Neuroendocrine Tumors

NCT04841148 2026-04-09

PALAVY

Phase 2 Recruiting

Breast Neoplasms, Neoplasm, Residual

NCT04792073 2026-04-07

Study of Avelumab and/or Radiation Therapy in People With Advanced Merkel Cell Carcinoma

Phase 2 Active not recruiting

Neoplasm Metastasis, Carcinoma, Merkel Cell

NCT04360941 2026-04-06

PAveMenT

Phase 1 Recruiting

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT04822350 2026-04-02

AVENANCE

596 enrolled 43 charts

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT03815643 2026-03-31

Avelumab Program Rollover Study

Phase 3 Active not recruiting

GenitourinaryGynecologicThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Ovarian Neoplasms

NCT04328844 2026-03-30

A Study to Assess a PI3Kδ Inhibitor (IOA-244) in Patients With Metastatic Cancers

Phase 1 Active not recruiting

DermatologicLymphoidMyeloidOther solid neoplasmThoracic

Uveal Melanoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Melanoma, Mesothelioma, Primary Myelofibrosis

NCT04261855 2026-03-27

GoTHAM

Phase 1/2 Active not recruiting

DermatologicEndocrineNET

Carcinoma, Carcinoma, Merkel Cell, Neuroendocrine Tumors

NCT04387084 2026-03-23

Short-term Fasting Prior to PD-1/PD-L1 Inhibitor Therapy for of Advanced or Metastatic Skin Malignancy

Phase 1 Active not recruiting

Skin Neoplasms

NCT06228066 2026-03-23

Lurbinectedin With or Without Avelumab in Small Cell Carcinoma of the Bladder (LASER)

Phase 2 Recruiting

Small Cell Lung Carcinoma

NCT04637594 2026-03-20

IMAGINE

Phase 3 Active not recruiting

3 enrolled 6 charts

Carcinoma, Transitional Cell

NCT03573648 2026-03-19

ImmunoADAPT

Phase 2 Active not recruiting

Breast Neoplasms

NCT03547973 2026-03-16

TROPHY U-01

Phase 2 Recruiting

827 enrolled 1 FDA

Metastatic Urothelial Cancer

NCT04004442 2026-03-13

COAXIN

Phase 1 Active not recruiting

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Ureteral Neoplasms, Urethral Neoplasms

NCT07460245 2026-03-10

AVESEC

Phase 2 Not yet recruiting

Carcinoma, Transitional Cell